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Background: Cisplatin based chemotherapy cures over 80% of metastatic testicular germ cell tumours (TGCT). In
contrast, almost all other solid cancers in adults are incurable once they have spread beyond the primary site. Cell
lines derived from TGCTs are hypersensitive to cisplatin reflecting the clinical response. Earlier findings suggested
that a reduced repair capacity might contribute to the cisplatin hypersensitivity of testis tumour cells (TTC), but the
critical DNA damage has not been defined. This study was aimed at investigating the formation and repair of
intrastrand and interstrand crosslinks (ICLs) induced by cisplatin in TTC and their contribution to TTC
hypersensitivity.
Results: We observed that repair of intrastrand crosslinks is similar in cisplatin sensitive TTC and resistant bladder
cancer cells, whereas repair of ICLs was significantly reduced in TTC. gH2AX formation, which serves as a marker of
DNA breaks formed in response to ICLs, persisted in cisplatin-treated TTC and correlated with sustained
phosphorylation of Chk2 and enhanced PARP-1 cleavage. Expression of the nucleotide excision repair factor ERCC1-
XPF, which is implicated in the processing of ICLs, is reduced in TTC. To analyse the causal role of ERCC1-XPF for
ICL repair and cisplatin sensitivity, we over-expressed ERCC1-XPF in TTC by transient transfection. Over-expression
increased ICL repair and rendered TTC more resistant to cisplatin, which suggests that ERCC1-XPF is rate-limiting
for repair of ICLs resulting in the observed cisplatin hypersensitivity of TTC.
Conclusion: Our data indicate for the first time that the exceptional sensitivity of TTC and, therefore, very likely the
curability of TGCT rests on their limited ICL repair due to low level of expression of ERCC1-XPF.
Background
Over 80% of patients with metastatic testicular germ cell
tumours (TGCT) can be cured using cisplatin-based
chemotherapy [1]. Since introduction of cisplatin in the
clinic it became a component of standard treatment of
ovarian, cervical, head and neck, lung and bladder can-
cer. Unfortunately, however, none of these malignancies
can be treated with a similar efficiency as TGCT [2].
Understanding why TGCT are sensitive to chemothera-
peutic drugs is likely to have implications for the
improved treatment of other types of cancer. Cell lines
derived from TGCT retain their exceptional sensitivity
to many chemotherapeutic drugs, reflecting the clinical
response [3]. Using testis tumour cell lines as a model
system may help to define the molecular basis for this
hypersensitivity [4].
The major DNA lesions induced by cisplatin are
intrastrand DNA crosslinks between two guanines or
guanine and adenine, accounting together for ~90% of
the platination lesions. In contrast, interstrand crosslinks
(ICLs) between the two DNA strands are minor lesions,
accounting for less than 5% of all cisplatin lesions [5].
Intrastrand crosslinks are repaired by nucleotide exci-
sion repair (NER), whereas ICLs are removed by ICL
repair, a process less well understood than NER [6].
A survey of repair proteins revealed that the expression
level of the ERCC1-XPF endonuclease, which is involved
in repair of both intrastrand crosslinks and ICLs, is low
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lines [7] suggesting that ERCC1-XPF might contribute
to the observed cisplatin sensitivity.
Previously, we showed that testis tumour cells (TTC)
remove DNA platination damage more slowly from the
whole genome and from single genes than cisplatin
resistant tumour cells indicating a deficiency in the
repair of DNA platination [8]. Here we extended this
study and investigated whether TTC are impaired in the
repair of ICLs, which have not been studied before in
TTC. As a model system we used TTC and bladder can-
cer cells as proven examples of cisplatin sensitive and
resistant cell lines, respectively [8]. We determined the
expression level and over-expressed ERCC1-XPF in
TTC and down-regulated the repair proteins in bladder
cancer cells. The data revealed for the first time that the
exceptional sensitivity of TGCT to cisplatin is associated
with a low capacity for repairing ICLs, and that levels of
ERCC1-XPF are rate-limiting. This is clinically impor-
tant as it demonstrates that ERCC1-XPF could be used
as a target to enhance the response of tumours to
ICL-inducing drugs.
Results
Removal of GpG-intrastrand crosslinks in TTC
To investigate cisplatin-damage repair in TTC, we
used the cell lines 833 K and SuSa and compared
them with MGH-U1 bladder cancer cells. Earlier stu-
dies using colony formation assays revealed a 3-fold
higher cisplatin sensitivity of 833 K and SuSa cells (for
comparison of sensitivity of TTC with bladder cancer
cells see Figure 1A) suggesting these lines represent a
useful model system for cisplatin sensitive and resis-
tant cells, respectively [8]. DNA intrastrand crosslinks
are the major DNA lesions induced by cisplatin. To
investigate whether repair of cisplatin-induced intras-
trand crosslinks is impaired in TTC, experiments were
performed to measure their removal from genomic
DNA. GpG-intrastrand crosslinks were detected using
a lesion-specific antibody [9]. Time-response curves
using MGH-U1 cells showed that GpG-intrastrand
crosslinks were formed directly after cisplatin treat-
ment, and at a higher level 6 h later (Figure 1B). This
is in line with previous findings showing that following
a 1 h cisplatin treatment the level of intrastrand cross-
links peaked after 4-6 h [10]. For repair experiments
we therefore treated the cells with cisplatin for 1 h and
determined the level of GpG crosslinks 6 h later (for
the maximum level of GpG adducts) and 24 h later for
determining their repair. The amount of GpG-intras-
trand crosslinks measured 6 h post-treatment was set
to 100%. The GpG-intrastrand crosslink levels mea-
sured 24 h post-treatment were corrected for dilution
due to DNA synthesis during the recovery period to
rule out a reduction of GpG damage because of DNA
replication. Quantification revealed that the initial
amount of GpG intrastrand crosslinks was about
50% lower in bladder cancer cells compared to TTC
(Figure 1C). Post-treatment removal of GpG-intras-
trand crosslinks in cells treated with cisplatin in shown
in Figure 1D. No reduction in the level of GpG-intras-
trand crosslinks was observed in XP12RO cells, which
are deficient in the NER protein XPA and were there-
fore included as a control for repair deficiency.
In MGH-U1 bladder cancer cells the amount of GpG-
intrastrand crosslinks was significantly reduced by 45%
after 24 h. This reduction was similar to that seen in
TTC where the amount of GpG-intrastrand crosslinks
was reduced by about 35% after 24 h. Since a repair
capacity of cisplatin-induced intrastrand crosslinks in
the range of 40-50% indicates repair proficiency [10],
the data indicate that TTC are able to repair cisplatin-
induced intrastrand adducts.
Induction and repair of ICLs in testis tumour cells
Induction and repair of cisplatin-induced ICLs was
investigated using a modification of the comet assay,
which permits detection of ICLs at the single cell level
[10]. Cisplatin-induced ICLs peak between 7-9 h post-
treatment (data not shown). Therefore, cells were trea-
ted with increasing concentrations of cisplatin for 1 h
and the amount of ICLs was determined 7 h later. The
level of ICLs increased in a concentration dependent
manner (Figure 1E). To measure the repair of ICLs,
cells were treated with cisplatin (15 μg/ml, 1 h) and the
amount of ICLs was determined 7 and 24 h after treat-
ment. As a control we used the ERCC1-deficient cell
line 43-3B [11]. The level of ICLs did not change in 43-
3B cells, which is in line with the observation that these
cells are deficient in ICL repair. For MGH-U1 cells the
ICL level was reduced by about 50% after 24 h suggest-
ing proficiency of repair of cisplatin-induced ICLs in the
bladder cancer cells (Figure 1F). No reduction in the
ICL level after 24 h was observed in 833 K cells, and a
small reduction in ICL level was observed in SuSa cells
indicating impaired ICL repair. Statistical analysis con-
firmed the difference in ICL repair capacity between
MGH-U1 and 833 K (p ≤ 0.001) and MGH-U1 and
SuSa (p ≤ 0.001). Taken together, the data revealed that
TTC are impaired in the repair of cisplatin-induced
ICLs.
Persistence of DNA damage in testis tumour cells
gH2AX formation can be used as a marker for DNA
damage (notably DNA double-strand breaks) associated
with ICLs [12]. We therefore treated the cells with
cisplatin for 1 h and stained for gH2AX 24, 48 and 72 h
post-treatment. Representative examples of gH2AX
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cells are shown in Figure 2A. gH2AX immunofluores-
cence was measured in more than 400 cells per time
point. The results were expressed as % of gH2AX posi-
tive cells, which were defined as having a fluorescence
signal above 500 units (Figure 2B). Over 90% of MGH-
U1 cells stained positive for gH2AX when analyzed 24 h
after cisplatin treatment, and the percentage of positive
cells was decreased 48 and 72 h post-treatment. In con-
trast, gH 2 A Xf o r m a t i o na f t e rc i s p l a t i nt r e a t m e n tp e r -
sisted in 833 K and SuSa cells (Figure 2B). It has been
suggested that following the induction of interstrand
crosslinks the persistence of gH2AX formation may
result from defective processing of ICLs [12]. The data,
therefore, support the conclusion of an impaired repair
of ICLs in TTC.
Chk1 and Chk2 phosphorylation by cisplatin treatment
The exact mechanism of how initial cisplatin lesions are
recognized and the signal becomes transmitted to the
apoptotic machinery is still not entirely clear [13]. How-
ever, both Chk1 and Chk2 have been implicated in cis-
platin damage signaling [14,15]. We therefore
investigated the phosphorylation of Chk1 and Chk2 at
different times following cisplatin treatment. PARP-1
cleavage was also investigated as a hallmark of apopto-
sis. Representative examples of immunoblots are shown
in Figure 3A, demonstrating that cisplatin induces acti-
vation of Chk1Ser317 and Chk2Thr68 as well as PARP-1
cleavage. PARP-1 cleavage was clearly more pronounced
in TTC lines than in MGH-U1 (Figure 3A), which is in
line with the higher apoptotic response in these cells
following cisplatin. Chk1 was transiently induced with a
Figure 1 Induction and removal of cisplatin-induced DNA lesions. A) Clonogenic cell survival curves of 833 K and SuSa testis tumour cells
and MGH-U1 bladder cancer cells after cisplatin treatment for 1 h. B) MGH-U1 bladder cancer cells were treated with cisplatin (7.5 or 15 μg/ml)
for 1 h, DNA was isolated 0 h, 6 h or 24 h post-treatment and examined for the presence of GpG-intrastrand crosslinks. C) MGH-U1 bladder
cancer cells, 833 K and SuSa testis tumour cells were treated with cisplatin (7.5 or 15 μg/ml) for 1 h. The levels of GpG-intrastrand crosslink were
determined 6 h post-treatment. D) MGH-U1 bladder, 833 K and SuSa testis and XPA-deficient XP12RO cells were treated with cisplatin (7.5 or 15
μg/ml) for 1 h, GpG-intrastrand crosslink levels were determined 6 and 24 h post-treatment. The levels measured 6 h post-treatment were set to
100%. The levels measured 24 h post-treatment were corrected for dilution due to DNA synthesis during the recovery period. Each point
represents the mean of 3 to 6 replicate experiments. E) MGH-U1 bladder (circles) and 833 K testis (squares) tumour cells were treated with
cisplatin for 1 h and analysed for ICL cross-linking 7 h post-treatment. The results are the means of three independent experiments. F) MGH-U1
bladder, 833 K and SuSa testis and ERCC1-deficient 43-3B cells were treated with cisplatin (15 μg/ml) for 1 h, the level of ICL cross-linking was
determined 7 and 24 h post-treatment. Each column represents the mean of 3 to 6 replicate experiments.
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treatment. For Chk2 a marked difference was observed
3 d after treatment where the activation occurred at
higher level in TTC lines than in MGH-U1 cells (Figure
3A and 3B). This was taken to indicate that checkpoint
activation occurs as a sustained response in TTC, pre-
sumably because of the presence of non-repaired DNA
lesions.
Effect of over-expression of ERCC1-XPF on ICL repair and
cisplatin sensitivity in testis tumor cells
The endonuclease ERCC1-XPF is implicated in the
repair of cisplatin-induced ICLs [16]. As the level of
ERCC1-XPF is low in TTC [7] we hypothesized that
ERCC1-XPF is the rate-limiting factor responsible for
the observed impaired ICL repair in TTC. 833 K cells
were transiently transfected with the bi-cistronic
Figure 2 gH2AX staining in bladder and testis tumour cell lines. A) Representative examples for MGH-U1 and 833 K cells treated with
cisplatin (6 μg/ml) for 1 h and stained for gH2AX at the indicated time points. C: untreated control. DNA counterstaining is with DAPI. B)
Quantification of gH2AX staining of MGH-U1 bladder, 833 K and SuSa testis tumour cells after exposure to cisplatin (6 μg/ml) for 1 h, followed by
a recovery period of 24, 48 or 72 h. For each data point, more than 400 nuclei/experiment were examined, the gH2AX fluorescence was
determined and the % cells with a fluorescence intensity more than 500 units (control value) were plotted. Each column represents the mean of
3 replicate experiments.
Usanova et al. Molecular Cancer 2010, 9:248
http://www.molecular-cancer.com/content/9/1/248
Page 4 of 11mammalian expression vector pEF6(XPF-IRES-ERCC1)
and the levels of ERCC1 and XPF proteins were investi-
gated. Immunoblot analysis showed an increase in both
ERCC1 and XPF proteins over time (Figure 4A). Over-
expression of ERCC1-XPF did not increase the level of
ICL repair in MGH-U1 (data not shown). However,
over-expression of ERCC1-XPF in 833 K cells resulted
in significant repair of cisplatin-induced ICLs (Figure
4B). When 833 K cells were transfected without DNA
(mock) or with a vector control (vector) we observed no
repair of ICLs (Figure 4B). Statistical analysis confirmed
the difference in ICL repair between 833 K untrans-
fected cells and ERCC1-XPF over-expressing cells (p ≤
0.001). Altogether these data suggest that over-expres-
sion of ERCC1-XPF abrogated the ICL repair deficiency
in TTC.
To investigate whether the increased ICL repair has an
impact on cellular sensitivity towards cisplatin, ERCC1-
XPF was over-expressed in 833 K cells before treatment
with cisplatin. The cells were treated with cisplatin
(12 and 15 μg/ml, 1 h) and apoptosis was determined
96 h post-treatment. Over-expression of ERCC1-XPF
clearly reduced the frequency of cells in subG1
indicating that ERCC1-XPF had a protective effect on
apoptosis induction by cisplatin (Figure 4C). These find-
ings suggest that low levels of ERCC1-XPF contribute to
cisplatin sensitivity in TTC. We should note that the
decrease in sensitivity was not dramatic, most likely
because of a low transfection efficiency usually observed
with TTC which are difficult to transfect because of
their extreme sensitivity towards most experimental
manipulations.
Effect of ERCC1-XPF down-regulation on cisplatin
sensitivity in MGH-U1 bladder cancer cells
As a proof of principle for demonstrating a contribution
of ERCC1-XPF for cisplatin sensitivity, we down-regu-
lated ERCC1-XPF in MGH-U1 cells using siRNA against
ERCC1. ERCC1 and XPF form a tight complex [17]. The
proteins are unstable and are rapidly degraded without
its partner [18]. It is therefore possible to reduce both
ERCC1 and XPF protein using siRNA against ERCC1.
We transiently transfected MGH-U1 cells with ERCC1
siRNA and investigated ERCC1 and XPF levels by
immunoblotting. A strong decrease of both ERCC1 and
XPF protein levels was observed (Figure 5A). To
Figure 3 Phosphorylation of Chk1 and Chk2 and PARP-1 cleavage in testis versus bladder cancer cell lines. A) Immunoblot analysis of
p-Chk1Ser317, p-Chk2Thr68 and cleaved PARP-1 in 50 μg protein extract of MGH-U1 bladder, 833 K and SuSa testis tumour cells. RPA2 was used as
a loading control. Cells were harvested at the indicated time points after treatment with cisplatin (6 μg/ml) for 1 h. B) Quantification of the data
obtained in immunoblots.
Usanova et al. Molecular Cancer 2010, 9:248
http://www.molecular-cancer.com/content/9/1/248
Page 5 of 11Figure 4 Effect of ERCC1-XPF over-expression on ICL repair
and cisplatin sensitivity. A) 833 K cells were transfected with
plasmid pEF6(XPF-IRES-ERCC1). Immunoblot analysis of XPF and
ERCC1 proteins in extracts harvested at the indicated time points.
RPA2 served as loading control. B) 833 K cells (non-transfected,
transfected with pEF6(ERCC1-IRES-XPF), transfected with vector pEF6,
mock transfected) were treated with cisplatin (15 μg/ml) for 1 h, the
level of interstrand crosslinking was determined 7 and 24 h post-
treatment. Each column represents the mean of 3 to 6 replicate
experiments. C) Cells were transfected with plasmid pEF6(XPF-IRES-
ERCC1) for 24 h, treated with cisplatin (12 and 15 μg/ml) for 1 h
and post-incubated for 96 h. Apoptosis was measured by flow
cytometry (sub-G1 content). * represents statistical significance.
Figure 5 Effect of ERCC1-XPF down-regulation on cisplatin ICL
damage and sensitivity. A) MGH-U1 cells were transfected with 10
nM ERCC1 siRNA and analysed 48, 72 and 96 h after transfection for
ERCC1 and XPF expression. RPA2 served as loading control. B) MGH-
U1 cells were transfected with 10 nM ERCC1 siRNA or control siRNA,
cultivated for 96 h, treated with cisplatin (6 μg/ml) for 1 h and post-
incubated for 24 or 48 h. gH2AX fluorescence was quantified in
MGH-U1 parental cells and cells transfected with either ERCC1 siRNA
or control siRNA. For each data point, more than 400 nuclei/
experiment were examined, the gH2AX fluorescence was
determined and the % cells with a fluorescence intensity more than
500 units (control value) were plotted. Each column represents the
mean of 3 independent experiments. C) MGH-U1 cells were
transfected with 10 nM ERCC1 siRNA or control siRNA, cultivated for
96 h, treated with cisplatin (9 μg/ml) for 1 h and post-incubated for
48 or 72 h. Apoptosis was measured by flow cytometry (sub-G1
content). * represents statistical significance.
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on cisplatin-induced ICL damage, cells were transfected
with ERCC1 siRNA, treated with cisplatin for 1 h and
investigated for gH2AX formation as a marker for
damage related to cisplatin ICLs 24 and 48 h later (Fig-
ure 5B). Between 80 and 90% of cells stained positive
for gH2AX when analyzed 24 h after cisplatin treatment.
In MGH-U1 parental cells and cells transfected with
control siRNA the percentage of positive cells was
decreased 48 h post-treatment. In contrast, gH2AX for-
mation after cisplatin treatment persisted in MGH-U1
cells transfected with ERCC1 siRNA (Figure 5B). These
data indicate that down-regulation of ERCC1-XPF lead
to impaired processing of ICLs in bladder cancer cells.
To further investigate the effect of down-regulation of
ERCC1-XPF on cisplatin sensitivity, cells were trans-
fected with ERCC1 siRNA, treated with cisplatin,
and apoptosis was determined 48 and 72 h later. Down-
regulation of ERCC1-XPF increased the sensitivity to
cisplatin, as shown by the higher level of apoptosis
(Figure 5C). The increase in sensitivity was statistically
significant but small, perhaps due to the relatively long
cultivation period following after siRNA transfection,
and variations in transfection efficiency. The data sup-
port the view that ERCC1-XPF is a key factor in deter-
mining cisplatin sensitivity of TTC.
Discussion
In this study, we demonstrate for the first time that
TTC are impaired in the repair of ICLs, which are
minor lesions formed in response to cisplatin. The
repair defect accounts, at least in part, for the sensitivity
towards cisplatin. We also identified ERCC1-XPF as a
factor underlying the impaired ICL repair. The observa-
tion of impaired ICL repair in TTC is supported by sus-
tained cisplatin-induced gH2AX formation, which was
paralleled by a late and sustained activation of Chk2 and
late PARP-1 cleavage. The importance of ERCC1-XPF
in processing ICLs has also been demonstrated in
ERCC1-deficient mouse and hamster cell lines. In
ERCC1 deficient MEFs persisting gH2AX foci were
shown after treatment with the ICL-inducing agent
MMC [16]. Similar data were obtained for cisplatin in
ERCC1 mutated UV96 hamster cells [12]. In renal cells
cisplatin lead to sustained activation of Chk2, which in
turn resulted in activation of the apoptotic pathway
[14]. We found sustained activation of Chk2 following
cisplatin treatment in TTC and conclude that persisting
ICLs result in DSB formation that lead to a long-term
DNA damage response and finally activation of the
apoptotic pathway [19].
In contrast to the deficiency in ICL repair, TTC were
proficient in removing intrastrand crosslinks. Cisplatin-
induced intrastrand crosslinks are removed by NER, and
our findings suggest that testis tumour cells are basically
NER proficient. This is supported by the finding that
833 K cells are capable of repairing UV-induced photo-
products, which are removed exclusively by NER [20].
These findings in living cells, however, are in contrast to
the low NER capacity, which was observed in experi-
ments using cell-free extracts of TTC lines including
833 K [21]. TTC lines have low levels of the NER pro-
teins XPA and ERCC1-XPF [7,21], and we hypothesize
that low levels of these proteins together with the short
incubation times applied are apparently inadequate to
sustain efficient NER in vitro a s s a y sw h i l et h e ya r e
apparently sufficient for performing NER in living cells.
The findings reported here also contrast with earlier
studies where it was shown that TTC remove DNA pla-
tination damage more slowly from the whole genome
and from single genes compared to bladder cancer cells
[8]. The discrepancy might be explained by considering
that in these earlier experiments removal of total plati-
nation was investigated, which is a quite crude measure
of DNA damage, while here the repair of GpG-intras-
trand adducts was studied using a highly sensitive
immuno-assay. In addition, in the experimental set-up
used earlier platination levels were measured directly
after cisplatin treatment and compared to the level 24 h
later, while here we compared the level of cisplatin-
induced intrastrand adducts 6 and 24 h post-treatment
because intrastrand adduct formation peaks at 6 h post-
treatment [10]. One could argue that the efficiency to
remove cisplatin-induced mono-adducts is reduced in
TTC while the resulting intrastrand crosslinks are
recognized by the NER system because they cause more
distortion of the DNA structure. This suggestion is sup-
ported by the observation that GpG-intrastrand cross-
link levels were higher in TTC compared to bladder
cancer cells. This, however, is unlikely to cause the
increased sensitivity of TTCs since earlier studies
showed that some bladder cancer cells exhibit up to 3
times the initial platination level compared to TTC, but
still were considerably more resistant to the drug [8].
In contrast to NER, the ICL repair pathway is not well
understood and a number of models for ICL repair have
been discussed [6]. In vitro and in vivo data implicate
the NER factor ERCC1-XPF in the repair of ICLs in
addition to its role in NER [16,17,22]. We tested the
hypothesis that low levels of ERCC1-XPF are responsi-
ble for the impaired ICL repair in TTC. Over-expression
of ERCC1-XPF resulted in ICL repair in 833 K cells sug-
gesting that low levels of ERCC1-XPF contribute to
impaired ICL repair, while the reduced levels of ERCC1-
XPF are still sufficient to perform NER in TTC. It is not
yet known at which level ERCC1-XPF becomes a rate-
limiting factor for NER. For the NER factor XPA we
found that levels of this protein had to be reduced to
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iting for NER [23]. It has been shown that the transient
participation time of XPA in a single NER event is 4 to
6 min [24], a similar dynamic behaviour was demon-
strated for ERCC1-XPF [25]. Possibly, even low levels of
XPA and ERCC1-XPF are sufficient due to the short
t i m eo fas i n g l eN E Re v e n t ,w h i l et h i sm i g h tn o tb et h e
case for the more complex ICL repair process.
A number of studies have implicated repair deficiency
as a reason for cellular sensitivity towards cisplatin. We
found that over-expression of ERCC1-XPF protein
increased the resistance of 833 K cells to cisplatin. The
effect was not dramatic most likely due to the fact that
833 K cells are sensitive to experimental manipulations
such as transfection. Nevertheless the data show that
ERCC1-XPF mediated ICL repair has a protective effect
on TTC and indicate that low ERCC1-XPF levels contri-
bute to cisplatin sensitivity in these cells. In support of
this we showed that down-regulation of ERCC1-XPF
rendered MGH-U1 bladder cancer cells more sensitive
to cisplatin. In line with this hypothesis is the finding
that acquired resistance towards cisplatin is often corre-
lated with an increased expression of ERCC1 [26,27]. In
clinical studies high ERCC1 expression was associated
with resistance to platinum containing therapy in var-
ious human cancers including colorectal cancer, ovarian
cancer or NSCLC [28-31]. Altogether the clinical studies
together with in vitro data suggest that ERCC1 may
serve as a reliable predictive marker for resistance to cis-
platin in human cancers.
The observation that the clinically relevant sensitivity
of TTC is, at the level of DNA, due to impaired ICL
repair, raises the interesting question about inhibition of
ICL repair as a strategy to increase the efficacy of che-
motherapy. In general, inhibition of DNA repair has the
potential to enhance the cytotoxicity of anticancer
agents. Preclinical studies have confirmed that modula-
tion of repair pathways such as base excision repair,
strand break repair, MGMT and PARP can enhance the
sensitivity to DNA damaging agents [32]. For a number
of repair inhibitors clinical studies are now under way
[33-35]. In order to inhibit the repair of ICLs different
approaches can be envisaged, with ERCC1 as a potential
key anticancer target. As ERCC1 has no known catalytic
activity, ERCC1-XPF or ERCC1-XPA protein-protein
interactions might be a target for sensitization strategies.
UCN-01, which reduces the ERCC1-XPA interaction,
has been shown to increase cisplatin toxicity [36]. How-
ever, enzymatic activities have proven to be more suc-
cessful targets than disruption of protein-protein
interactions. Therefore, targeting the endonuclease activ-
ity of XPF directly might also be a successful approach.
Thus, our findings on TTC may encourage the search
for strategies aimed at sensitizing other cancers to
cisplatin-based chemotherapy by inhibiting ICL repair.
Conclusion
Our study identified ICLs as critical cytotoxic lesions
induced by cisplatin in TTC, which are not repaired
because of a low level of expression of ERCC1-XPF.
Therefore, the repair complex ERCC1-XPF appears to
be responsible at DNA level for the exquisite cisplatin
sensitivity of testis tumors. Overexpression of ERCC1-
XPF resulted in repair of cisplatin induced ICLs and
decreased cisplatin sensitivity suggesting that persisting
ICLs in TTC trigger DSB formation (as demonstrated
by gammaH2AX) that in turn activates the apoptotic
pathway. Our study suggests that targeting ERCC1-XPF
might be a strategy for improving the therapeutic
efficacy of cisplatin for other types of cancer.
Materials and methods
Cell culture and cisplatin treatment
833 K and SuSa human TGCT cell lines, MGH-U1
bladder carcinoma cells and XPA-deficient XP12RO
were described previously [7,23]. 43-3B is an ERCC1-
deficient CHO hamster cell line [11]. All cell lines were
grown in RPMI 1640 medium supplemented with 10%
heat-inactivated fetal calf serum, L-glutamine (PAA) and
5% antibiotics (penicilline/streptavidine). For drug treat-
ment cells were incubated with cisplatin for 1 h at 37°C
in a humidified atmosphere.
Determination of apoptosis
Apoptosis was measured by flow cytometry (sub-G1
content). After treatment with cisplatin and postincuba-
tion in fresh medium, cells were harvested, fixed with
ethanol (70%) and stained with propidium iodide (17
μg/ml) after RNase (30 μg/ml) digestion. Samples were
analyzed on a FACSCalibur (Becton Dickinson, Ger-
many). Accumulated data were analyzed using WinMDI
Software.
Colony formation assays
Colony formation assays were performed according
to [8].
Construction of mammalian expression vector
ERCC1 and XPF cDNAs were cut from plasmid pET30B
(+)ERCC41 [37]. XPF cDNA between restriction sites
XbaI and Not I was ligated into the mammalian expres-
sion vector pEF6 (Invitrogen) digested with SpeI and
NotI. ERCC1 cDNA between XbaI restriction sites was
ligated into pEF6(XPF) digested with XbaI. IRES
sequence was amplified by PCR using primers with
5’ends complementary for the NotI restriction site. The
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pEF6(XPF-ERCC1). The resulting vector pEF6(XPF-
IRES-ERCC1) was used for transfection studies.
Transfection experiments
To over-express ERCC1-XPF transient transfections
were performed. Cells were incubated for 24 h with
medium containing Effectene transfection reagent (Qia-
gen) and 2 μgo fv e c t o rp E F 6 ( X P F - I R E S - E R C C 1 )o r2
μg of vector pEF6 containing no insert. After transfec-
tion the cells were washed and treated with cisplatin for
1 h. Transient knock-down of ERCC1 was achieved by
transient transfection of 10 nM ERCC1 siRNA (Dhar-
macon RNA technologies: D-006311-02). siRNA was
delivered using Dharmacon siRNA transfection reagent
according to the manufacturer’s instructions. A non-tar-
geting siRNA was used in control experiments and was
purchased from Qiagen (AllStars Negative Control
siRNA).
Detection of GpG-intrastrand crosslinks with lesion
specific antibody
Cells were treated with cisplatin for 1 h and harvested
immediately or incubated in fresh medium for another 6
or 24 h. DNA was isolated using the Master-Pure™
Complete DNA and RNA Purification kit (Epicentre®
Biotechnologies, USA). For each time point 4 μgD N A
was used in duplicate for detection of cisplatin-induced
GpG adducts. DNA was denatured (95°C for 10 min)
and placed on ice immediately. Ice-cold ammonium
acetate was added (final concentration 1 M), DNA was
applied to a nylon Hybond-N+ membrane (Amersham)
using a slot blot apparatus (Hybridot Manifold, Bethesda
Research Laboratories). The membrane was washed with
ammonium acetate (1 M), incubated in 5 × SSC for 5
min and washed in water. The DNA was fixed onto the
membrane by baking at 80°C for 2 h. The membrane
was blotted in PBS/0,2% Tween-100, 5% non-fat dry
milk for 2 h, incubated with an antibody specific for
GpG-intrastrand crosslinks [9] at a dilution of 1/500 at
4°C overnight. Peroxidase-conjugated secondary anti-rat
antibody (1/2,000) was used for 2 h in blocking buffer.
GpG-intrastrand crosslinks were visualized by chemilu-
minescence. SynGene software was used for quantifica-
tion. The percentage of lesions remaining at 24 h was
calculated in comparison to the lesions present 6 h
post-treatment. To assess DNA synthesis during the
recovery period, cells were labeled with 50 nCi/ml [
14C]
thymidine for 24 h prior to cisplatin treatment. Dilution
factors (specific activity of DNA at time point/specific
activity of DNA at 0 h) were determined for the 24 h
repair period.
Determination of cisplatin-induced interstrand
crosslinking, statistical analysis
The detection of interstrand crosslinking was investigated
using a modification of single cell gel electrophoresis
(comet assay) as described previously [10]. Exponentially
growing cells were treated with cisplatin for 1 h, harvested
after 7 h and 24 h and diluted to a density of 2.5 × 10
4
cells/ml. All cisplatin-treated samples and one control
were subjected to 8 Gy X-irradiation to induce random
strand breakage, one unirradiated control was also
included. The cells were lysed and subjected to electro-
phoresis. The presence of ICLs retards migration of the
irradiated DNA during electrophoresis, resulting in
reduced tail moment compared to control cells. To pre-
vent repair of DNA breaks after irradiation, cells were
kept on ice. Immediately after irradiation the cells were
embedded in 0.5% low melting point agarose on micro-
scope slides which were pre-coated with with 0,5% low
melting point agarose. After the agarose solidified, the
slides were placed in cold lysis buffer (2.5 M NaCl,
100 mM EDTA, 10 mM Tris, 1% Na-Laurylsarcosinate,
pH 10) and incubated for 1 h at 4°C, followed by incuba-
tion in alkaline electrophoresis buffer (300 mM NaOH,
1 mM EDTA, pH > 13) for 30 min to denature DNA.
Electrophoresis was carried out for 15 min at 25 V in the
dark. Following electrophoresis the slides were incubated
in neutralization solution (0.4 M Tris pH7.5) 3 × for
5 min, rinsed with H2O and fixed with absolute ethanol
for 5 min. Slides were allowed to dry overnight, stained
with propidium iodide (50 μg/ml), and comets were ana-
lyzed using a Nikon MIKROPHOT FXA fluorescence
microscope. Fifty cells per slide were analyzed using
Komet 4.0.2 Assay Software (Kinetic Imaging Ltd, Liver-
pool). The value of the tail moment was used to describe
t h er a t eo fm i g r a t i o no fD N Ao u to ft h en u c l e u sd u r i n g
electrophoresis. The tail moment is calculated as product
of percentage of DNA in the comet tail and distance
between the head and tail. The presence of ICLs retards
migration of the irradiated DNA during electrophoresis,
resulting in a reduced tail moment compared to the
untreated control. The amount of ICLs was therefore
determined by comparing the tail moment of the irra-
diated cisplatin-treated samples with irradiated untreated
samples and unirradiated untreated controls. The level of
interstrand crosslinking is proportional to the decrease in
tail moment (DTM) in the irradiated drug treated sample
compared to the irradiated untreated control. The %
DTM was calculated using the following formula
described by [10]: % DTM = [1 - (TMDI R-T M CU )/(TMC
IR -T CU )] × 100, where TMDI Ris the mean tail moment
of the cisplatin treated irradiated sample, TMCI Ris the
mean tail moment of the irradiated control sample and
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trol sample. Statistical analysis using the software program
SPSS (SPSS Inc., USA) was performed using % DTM of
150-200 cells. Kruskal-Wallis one-way analysis of variance
by ranks was used to compare whether ICL repair capacity
differed within the group of four cell lines. To compare
two independent groups of sampled data Mann-Whitney
Ut e s tw a su s e d .
gH2AX immunocytochemistry
Cells were plated at a density of 3 × 10
5 per dish on cover
slips in 60 mm dishes and incubated for 24 h at 37°C. The
cells were treated with cisplatin (6 μg/ml) for 1 h and
incubated in fresh medium for 24, 48 and 72 h, respec-
tively. Cells were quickly rinsed with PBS and then fixed
with 4% formaldehyde for 20 min at RT, followed by ice-
cold methanol absolute at -20°C for up to 72 h. The fixed
cells were blocked with 5% BSA in PBS/0.3% Triton-X100
for 1 h at RT and then incubated with a 1:1,000 dilution of
anti-phospho H2AXSer139 antibody (Millipore) over night
at 4°C. After washing 3 times in PBS the samples were
incubated with a 1:500 dilution of a Alexa-fluor 488 conju-
gated goat anti-mouse antibody (Invitrogen) for 1-2 h at
RT in the dark, followed by staining with DAPI (100 ng/
ml) for 30 min. 10 μl mounting medium was added, and
the cover slips containing the cells were mounted onto
microscope slides. Fluorescence images were captured
using a Zeiss microscope (ImageM1 AX10) and analysed
using Metafer software (MetaSystems).
Immunoblotting
Protein extraction and SDS gel electrophoresis were per-
fomed according to [7]. The antibodies used were: XPF
1/5,000 dilution of polyclonal antibody RA1 [21];
ERCC1 1/1,500 dilution of polyclonal antibody RWO18
[17]; RPA2 1/5,000 dilution of monoclonal antibody
9H8 (NeoMarkers); phospho-Chk1 1/1,000 dilution of
polyclonal antibody (Bethyl Laboratories); phospho-
Chk2 1/1,000 dilution of polyclonal antibody (Epi-
tomics); PARP-1 1/1,000 dilution of monoclonal anti-
body raised against amino acids 22-219 (BD); anti-rabbit
IgG 1/2,000 dilution (DAKO) or anti-mouse IgG 1/
5,000 dilution (DAKO). RPA2, which is a housekeeping
protein, was used as loading control since our previous
data showed relatively little variation in RPA2 levels for
different cancer cell lines [7].
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